Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03000179 · OUTCOME

Duration of Response

Safety and Efficacy of Avelumab in Small Intestinal Adenocarcinoma · Source last updated 2022-04-14

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
Full Range
Time frame
Date of first partial or complete response as defined by RECIST 1.1 criteria to date of recurrence or disease progression up to 3 years

What was measured

Time from tumor response date to disease progression or death for any reason.

Analysis population: Patients who had partial response.

Groups in this outcome

Avelumab Monotherapy

Participants receive avelumab by IV infusion following pretreatment with H1 blockers and acetaminophen once every 2 weeks. Avelumab: Avelumab through a vein once every 2 weeks

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Avelumab Monotherapy2

Reported measurements

Source class 1
Values in months · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Avelumab Monotherapy10.9Not reported3.018.8Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        3.0
        upper Limit
        18.8
        value
        10.9
denoms
  1. counts
    1. group Id
      OG000
      value
      2
    units
    Participants
description
Time from tumor response date to disease progression or death for any reason.
dispersion Type
Full Range
groups
  1. description
    Participants receive avelumab by IV infusion following pretreatment with H1 blockers and acetaminophen once every 2 weeks. Avelumab: Avelumab through a vein once every 2 weeks
    id
    OG000
    title
    Avelumab Monotherapy
param Type
MEDIAN
population Description
Patients who had partial response.
reporting Status
POSTED
time Frame
Date of first partial or complete response as defined by RECIST 1.1 criteria to date of recurrence or disease progression up to 3 years
title
Duration of Response
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice